Business Wire

WuXi Biologics Awarded an ISPE Facility of the Year Award in the Operations Category


IPS-Integrated Project Services, LLC, a leading provider of engineering, procurement, construction management, and validation (EPCMV) services, congratulates WuXi Biologics Ireland Limited (WuXi Biologics) for receiving a Facility of the Year Award (FOYA) from The International Society for Pharmaceutical Engineering (ISPE) in the Operations category for their Large-Scale Manufacturing Facility in Mullagharlin, Dundalk, Ireland. The IPS team of experts provided a range of services for the project, including process design, engineering, architecture, construction management, and validation support.

This press release features multimedia. View the full release here:

To view this piece of content from, please give your consent at the top of this page.

WuXi Biologics' Large-Scale Manufacturing Facility in Mullagharlin, Dundalk, Ireland. (Photo: Business Wire)

The ISPE Facility of the Year Awards (FOYA) program recognizes state-of-the-art pharmaceutical manufacturing facilities utilizing innovative design and construction strategies to produce high-quality, safe, cost-effective medicines. WuXi Biologics was recognized for its cutting-edge biologics manufacturing facility in Dundalk, Ireland. The FOYA judges found this project “an inspiring landmark that proves that facilities can be developed on a highly accelerated schedule, using innovative solutions while complying with regulatory requirements, overcoming unknown barriers, cooperation with the community, and upholding project success and product safety.”

Brendan McGrath, Vice President and Head of WuXi Biologics Ireland site, commented, "This recognition by ISPE is a testament to our team's dedication and relentless pursuit of excellence. We are also extremely grateful for the exceptional work of IPS, our facility designer, whose expertise significantly contributed to our achievement. This award signifies success not only for our team but also for our clients, partners, and local community. Ultimately, it's a victory for the patients who rely on the life-saving biologics manufactured at our Ireland site."

The WuXi Biologics facility is one of the world’s largest contract manufacturing single-use bioreactor sites. However, the facility’s real achievement is its unprecedented flexibility in cell culture-based manufacturing regardless of batch size by “scaling out” with 12 ABEC 4,000-liter capacity bioreactors. The facility’s flexible array of highly-configurable systems and overall capability to adapt to almost any perfusion, fed-batch, concentrated fed-batch, and intensified fed-batch techniques reduce client risk. This capability, combined with innovations in automation, single-use materials, and transition time, transforms the WuXi Biologics facility into a game changer for the production of emerging antibody-based therapies on a global impact.

The project was the first in Ireland to be delivered using an innovative design-assist model. IPS developed design packages to 60% detailed design; the remaining 40% was completed with engagement from the construction team, including subcontractors. This collaborative approach improved constructability, reduced time/cost, and significantly reduced rework. The single-use technology allows for a capacity of 48,000L, making it the largest single-use bioreactor in Ireland and possibly all of Europe.

The fast-track project was completed with over 6.2 million work hours in 26 months, with an average of 2,200 employed at peak. A total of 7,610 personnel were inducted on-site. Throughout construction in 2019 and 2020, more than 75 archaeologists were empowered to dig at sites spread across the campus. The artifacts found on the site depict common and extraordinary life spread across thousands of years—everything from fine sewing needles carved from bone to medieval spearheads and a cache of shiny 10th-century coins. WuXi Biologics maintained the schedule during their archaeological preservation and COVID challenges.

“IPS has been a partner to WuXi Biologics since its early days, and it is great to see it win the prestigious Facility of the Year Award. I still remember the early days of this project conception and when WuXi Biologics procured the massive site in Dundalk. Seeing the fantastic conclusion of all the efforts that followed is truly memorable. We are honored to have been part of this state-of-the-art facility which truly represents innovation, cutting-edge technology, and excellence. Congratulations to WuXi Biologics on this incredible achievement,“ said Dave Goswami, PE, IPS Chairman and Chief Executive Officer.

Cell-based therapeutics are transforming modern medicine, and WuXi Biologics’ facility is highly flexible and adaptable, ensuring the facility will have the capacity to produce a variety of new cellular therapies for years to come.

About IPS

IPS, a Berkshire Hathaway Company, is a global leader in developing innovative business solutions for the biotechnology and pharmaceutical industries. Through operational expertise and industry-leading knowledge, skill, and passion, IPS provides consultancy services, architecture, engineering, project controls, construction management, and compliance services that allow clients to develop and manufacture life-impacting products. Its newest acquisition, Linesight, specializes in cost, schedule, risk, program, and project management services in various market sectors, including data centers, life sciences, and high-tech industrial. With the addition of Linesight, IPS has over 3,000 professionals in over 45 offices across 17 countries in the Americas, Europe, Asia Pacific, Southeast Asia, Australia, and the Middle East. For further information, please visit

About WuXi

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2022, WuXi Biologics is supporting 588 integrated client projects, including 17 in commercial manufacturing.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability. For more information about WuXi Biologics, please visit

About the ISPE Facility of the Year Awards Program

Established in 2005, The Facility of the Year Awards (FOYA) recognize state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery. The FOYA program provides a platform for the pharmaceutical science and manufacturing industry to showcase its accomplishments in facility design, construction, and operation, while sharing the development of new applications of technology and cutting-edge approaches. Visit for more information.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Dept. of Marketing and Communications
+44(0) 121 289 3471

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IPS Appoints Jim Stephanou as New CEO5.6.2023 20:30:00 CEST | Press release

IPS, a leading provider of architecture, engineering, procurement, construction management, and validation services for the life sciences sector, announces the appointment of Jim Stephanou, as its new Chief Executive Officer (CEO) to lead the company into its next phase of growth. This press release features multimedia. View the full release here: IPS is excited to announce the appointment of Jim Stephanou as its new Chief Executive Officer (CEO) to lead the company into its next phase of growth. (Photo: Business Wire) Mr. Stephanou is a well-recognized and accomplished leader in the Pharmaceutical Industry with over thirty years of experience in manufacturing operations and engineering. His most recent role was Vice President, Global Engineering Solutions at Merck & Co., Inc., a position he held for eight years. During that time, he was responsible for managing and overseeing one of the largest capital investment cycles of any

Translated Unleashes Full GPT-4 Potential for Businesses Operating in Languages Other Than English5.6.2023 17:06:00 CEST | Press release

In a significant breakthrough for generative AI and content creation, Translated, a leader in AI-enabled language solutions, is proud to introduce its innovative language model T-LM (Translated Language Model). T-LM will help unlock the full potential of OpenAI’s GPT-4 for businesses around the world. It provides companies with a cost-effective solution to create and restructure content in 200 languages, bridging the performance gap between GPT-4 in English and non-English languages. This press release features multimedia. View the full release here: (Graphic: Business Wire) Until now, GPT's impressive performance has been a privilege of the English-speaking world. Companies operating in languages other than English have often found their performance lagging behind that of GPT models from several years ago, with some languages trailing by as much as three years. For these companies, the performance gap in understanding, generati

Wipro VisionEDGE to Power Bowling Center TV’s New Digital Out-of-Home Network5.6.2023 14:58:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced its dynamic digital signage solution, Wipro VisionEDGE, will power Bowling Center TV (BCTV), a new digital out-of-home television network distributed across bowling centers in the United States. BCTV is a partnership between Strike Ten Entertainment, the Bowling Proprietors’ Association of America (BPAA), and Equity Sports Partners. BCTV is supported by a best-in-class team of technology partners, including Cisco and Wipro VisionEDGE, and is designed to transform bowling center entertainment, revolutionize the way audiences engage with this popular sport, and how brands engage with those audiences. “Wipro VisionEDGE and BCTV represent a significant breakthrough in the digital signage and out-of-home industry, enabling targeted customer engagement,” said Malay Joshi, Senior Vice President and Sector Head of Communications, Retail, Connectivity & Services, Wipro Limit

Adva Network Security and Quantum Optics Jena showcase German-made QKD solution5.6.2023 14:00:00 CEST | Press release

Adva Network Security and Quantum Optics Jena today announced a successful joint demo of entanglement-based quantum key distribution (QKD) technology. The field trial leveraged quantum key generation and verification technology from Quantum Optics Jena in combination with Adva Network Security’s Layer 1 encryption solution to establish a secure optical communication channel between data centers owned and operated by the Thüringer Landesrechenzentrum (TLRZ), the IT service provider for the state’s administration in Thuringia. The test represents a milestone in the development of entanglement-based commercial QKD systems, as it is the world’s first complete integration into an IT infrastructure. By delivering quantum-secured keys to the encryptor of the high-bitrate optical channel, the team was able to show how data traffic could resist quantum attacks on the link between the data centers. The demo represents a significant leap forward for quantum-safe communications made in Germany and

Q4 Inc. Introduces First-of-its-Kind IR Event Management App to the Q4 Platform5.6.2023 14:00:00 CEST | Press release

Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, is excited to introduce the Event Management App to the Q4 Platform, which will enable clients to experience streamlined event preparation, management, and reporting for earnings, investor days, and other key events on their IR calendar. This press release features multimedia. View the full release here: Q4 Event Management (Graphic: Business Wire) The Q4 Event Management App will increase client control over every part of their event planning, saving time and centralizing all requests to simplify the planning process. With this novel approach, Investor Relations Officers (“IROs”) will be able to eliminate lengthy communication threads and redundant requests by saving event details and preferences for all future engagements. Clients will continue to benefit from a 99%+ platform reliability rate and the experience of hosting thousands of ear